Probenecid is named as an intervention in 3 current clinical trials in our USA, Germany and Canada registers. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Merck Sharp & Dohme LLC (1). The most-studied condition is Healthy.
Probenecid was first approved in the US on 26 Apr 1951.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
NCT04939623 · ClinicalTrials.gov ↗ · Chronic Pain, Drug Dependence of Morphine Type, Symptom, Withdrawal
|
Phase 2 | Recruiting | University of Calgary | Canada |
|
A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
NCT07840612 · ClinicalTrials.gov ↗ · Healthy
|
Phase 1 | Not yet open | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Germany |
|
A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)
NCT07661108 · ClinicalTrials.gov ↗ · Healthy
|
Phase 1 | Active, closed | Merck Sharp & Dohme LLC | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 1 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1 |
| University of Calgary | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in Germany | 1 | 0 |
| Clinical trials in Canada | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Germany and Canada registers name Probenecid as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Merck Sharp & Dohme LLC (1), Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) and University of Calgary (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Probenecid works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Probenecid works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Probenecid (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.